Q2 2024
Released Aug 8, 2024, before the open
10-Q filed Aug 8, 2024, 39 days after period end · 0001628280-24-035893
Q2 2024 · 10-Q
Revenue$0.00$0.00 — vs Q2 2023−100.0% vs Q1 2024
Net Income-$55.33M-$55.33M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.46-$0.46 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$55,672,000N/M
Operating Cash Flowderived-$45,491,000N/M
Free Cash Flowderived-$47,393,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — |
| Net Income | -$55.33M | -$42.39M | -$29.35M | $616.00K |
| EPS Diluted | -$0.46 | -$0.47 | -$1.76 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR